Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Denis Soulières et al.|The Lancet|2018Cited by 1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q.M. Chow, Tanguy Y. Seiwert, Robert I. Haddad et al.|Journal of Clinical Oncology|2016Cited by 859
Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With CisplatinJosé Baselga, John Mendelsohn, David G. Pfister et al.|Journal of Clinical Oncology|2000Cited by 746
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018A. Dimitrios Colevas, Susan Darlow, Sue S. Yom et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 632
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012Ranee Mehra, Robert I. Haddad, Tanguy Y. Seiwert et al.|British Journal of Cancer|2018Cited by 457